ČEŠKOVÁ, Eva and Jaromír ŠVESTKA. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry. Stuttgart-New York: Georg Thieme Verlag KG, 1993, vol. 26, No 4, p. 121-124. ISSN 0176-3679.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses
Name in Czech Dvojitě slepé srovnání účinků risperidonu a haloperidolu u schizfrenie a schizoafektivní psychózy
Authors ČEŠKOVÁ, Eva (203 Czech Republic, guarantor) and Jaromír ŠVESTKA (203 Czech Republic).
Edition Pharmacopsychiatry, Stuttgart-New York, Georg Thieme Verlag KG, 1993, 0176-3679.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30000 3. Medical and Health Sciences
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
RIV identification code RIV/00216224:14110/93:00003726
Organization unit Faculty of Medicine
UT WoS A1993LU64700003
Keywords in English risperidone; haloperidol; double-blind; schizophrenic; schizoaffective
Tags double-blind, haloperidol, risperidone, schizoaffective, schizophrenic
Changed by Changed by: prof. MUDr. Eva Češková, CSc., učo 726. Changed: 23/6/2009 09:39.
Abstract
A double-blind eight-week study was carried out to compare the efficacy and safety of risperidone in relation to haloperidol. Sixty-two inpatients suffering from acute schizophrenic or schizoaffective psychoses diagnosed according to ICD-9 were treated with risperidone 2-20 mg daily or haloperidol 2-20 mg daily. The mean total BPRS scores were reduced from 45.5 to 32.4 in the risperidone group and from 43.1 to 28.5 in haloperidol group. There were no significant differences between the two treated groups with regard to the total BPRS score and the percentage of remissions achieved. No statistically significant difference was found between the groups in any of the factors or items except guilt feeling (p < 0.02), anxiety (p < 0.005), and factor I - anxiety/depression - (p < 0.02) in favour of haloperidol. Risperidone had the benefit of a lower incidence of extrapyramidal side-effects.
Abstract (in Czech)
Dvojitě slepé srovnání účinků risperidonu a haloperidolu u schizfrenie a schizoafektivní psychózy
PrintDisplayed: 9/10/2024 15:01